Australian equity managers are backing biotech CSL despite its falling share price and unsuccessful vaccine trials, stating it is likely to be a recovery beneficiary. ...
After announcing it is producing a COVID vaccine, Money Management looks at which funds have the highest allocation to the biotech company....
Government backbenchers have pointed to evidence that AustralianSuper chief executive, Ian Silk, spoke to a critic of the Victorian Government COVID-19 lockdown as eviden...
Robeco believes healthcare companies should be subject to stronger ethics and sustainability research with those meeting higher criteria being rewarded with higher valuat...
Australian investors are now choosing stocks over property and other investments, according to a survey. ...
The current state of market offers great opportunities for contrarian investors with a focus on fundamentals, Allan Gray’s chief investment officer said....
Fidelity has identified three sectors that are attractively priced for investors looking to pick up blue-chip stocks at cheap prices following the COVID-19 fallout....
Might be a bit different to i the past where at most there was one man from the industry on the loaded enquiry boards a...
Who get's the $10M? Where does the money go?? Might it end up in the CSLR to financially assist duped investors??? ...
My view is that after 2026 there will be quite a bit less than 10,000 'advisers' (investment advisers) and less than 100...